NASDAQ · MRSN
Healthcare · Biotechnology
$29.08
Up+$0.00 (+0.00%)
Updated Aug 14, 2026, 7:12 AM
SID Score
4.2/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
MRSN does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning MRSN.
MRSN research
Company profile and research snapshot.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Nov 14, 2025 | Guggenheim | Neutral | — |
| Nov 13, 2025 | BTIG | Neutral | — |
| Nov 13, 2025 | Truist Securities | Hold | — |
| Aug 14, 2025 | Truist Securities | Buy | — |
| Aug 14, 2025 | Guggenheim | Buy | — |
No generated briefing is available yet.
prnewswire.com · Nov 28, 2025
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning MRSN.
